CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Ketorolac Tromethamine 30 MG/ML +1 moredrug
Likely dose
Ketorolac Tromethamine 30 MG/MLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03805607
NCT03805607Phase 4Completed

Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery

Beth Israel Deaconess Medical Center·interventional·Posted Jan 15, 2019·Updated May 29, 2026

In Brief

A Phase 4 clinical trial evaluating Ketorolac Tromethamine 30 MG/ML and Placebos for Analgesia, Obstetrical and 6 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. The investigators plan to use Platelet Aggregometry and Thromboelastography (TEG) to evaluate the effect of ketorolac on platelets.

Study Details

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJan 15, 2019
Enrollment StartJan 18, 2021
Primary CompletionFeb 3, 2022
Study CompletionMar 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.5 years ago

Interventions

Ketorolac Tromethamine 30 MG/MLdrug

Ketorolac 30 mg

Placebosdrug

Normal Saline